One of the most important features of prostate cancer (PC) is the diverse biological activity attributed to heterogeneity within individual cancers. We hypothesize that metabolic difference identified by proton MR-spectroscopy (MRS) might be related to diverse biological potential resulting from heterogeneous cancer cell populations and well reflect the biological aggressiveness of PC.
INTRODUCTION AND OBJECTIVES:
One of the most important features of prostate cancer (PC) is the diverse biological activity attributed to heterogeneity within individual cancers. We hypothesize that metabolic difference identified by proton MR-spectroscopy (MRS) might be related to diverse biological potential resulting from heterogeneous cancer cell populations and well reflect the biological aggressiveness of PC.
METHODS: In this study, 113 cases that underwent RALP were included. All patients performed 1.5T MRS examination prior to RALP. On MRS, each peak of the chemical shift between 0.5 and 4.2 ppm was determined by the computer-assisted objective measurement of MRS, and evaluated by cluster analysis or principal component analysis for measuring heterogeneity within individual cancers. The 1st principal component was considered as an index related to heterogeneity within individual cancers. The mean value, standard deviation (SD), coefficient of variation (CV) of the target shifts such as choline (3.2 ppm), citrate (2.6 ppm), N-acetyl-L-aspartate (NAA) (2.0 ppm) and alanine (1.48 ppm) were also calculated and compared with pathological findings as well as biochemical recurrence (BCR).
RESULTS: Representative heatmaps of 2 different PC cases were shown in Figure. In this study, a correlation between the mean value and SD was positive in choline and NAA, (p<0.0001, both), while it was weak in alanine (p¼0.0479). Based on this, the SD was used as an index of variation for choline and NAA, while the CV was used for alanine. The measured mean heterogeneity of our series predicted by the 1st principal component was 21.4%, which showed a significant correlation with SD for choline and NAA (p¼0.0011and p<0.0001, respectively). On the other hand, the 1st principal component did not correlate with the CV for alanine, PSA or Gleason score. Although 8 out of 113 patients progressed into BCR, multivariate analysis showed that the SD for choline, followed by PSA and the SD for NAA, was an independent predictor of BCR (p¼0.0354, p¼0.0624 and p¼0.0952, respectively).
CONCLUSIONS: To our knowledge, this is the first report of comprehensive analysis of MRS pattern to validate intra-tumor heterogeneity in PC, which can surely develop diagnostic and therapeutic strategy of PC. (ccRCC) is the most common histology among these SRMs. Current AS algorithms largely rely on growth parameters of the masses measured over time. We sought to identify genomic biomarkers that could potentially refine the management of SRMs, especially in patients being evaluated for AS.
Source of
METHODS: From four databases, we identified 205 patients who had SRMs (<4 cm) at time of surgery and had sequencing performed on their primary tumors. We included patients from our institutional prospective database (n¼25), and from three publicly available cohorts, The Cancer Genome Atlas (n¼110), University of Tokyo (n¼38), and The International Cancer Genome Consortium (n¼32). We analyzed the frequency of recurrent somatic mutations among the entire cohort. Using Chi-Square analysis, the frequency of mutations that occurred in at least 5% of patients were compared in patients who had recurrence or died from their disease during follow-up with those who did not. Kaplan-Meier survival plots were generated for these frequently mutated genes. Analysis was adjusted for multiple testing using the false discovery rate.
RESULTS: Median follow-up was 43.1 months among survivors. Mutations in VHL, PBRM1, SETD2, BAP1, KDM5C, and MTOR were present in more than 5% of tumors. Of the 205 patients, 25 (12.2%) had recurrence or died of their disease. Mutations in KDM5C were found to be significantly more common in those who had recurrence or died of their disease (24% vs. 4%; adjusted p¼0.02). Survival analysis showed patients with KDM5C having statistically significant inferior cancer-specific survival (adjusted p¼<0.01) and a trend for inferior survival in those with SETD2 mutations (adjusted p¼0.11) (Figure 1) . CONCLUSIONS: We identified mutations in SRMs that are associated with recurrence and lethality. The strongest association was seen with KDM5Cmutations. Use of these potential genomic biomarkers may improve risk stratification of patients with SRMs and for those who may be appropriate for AS. Prospective evaluation of these markers is needed.
INTRODUCTION AND OBJECTIVES: Evaluation of genetic divergence among primary (P) and metastatic (M) tumors in renal cell carcinoma (RCC) is limited to small or unmatched P-M cohorts. We aim to better characterize somatic mutation (SM) disparities in a cohort of matched P-M tumors.
METHODS: We prospectively sequenced 47 clear cell RCC (ccRCC) and 12 non-clear cell RCC (nccRCC) P-M matched pairs using Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT), a custom 410-gene (previously 341) next-generation sequencing assay.
RESULTS: We detected 527 SM, with a mean (SD) of 4.5 (3.13) per sample. Overall concordance rate (shared mutations/total mutations) was 49% (46% for ccRCC vs 78% for nccRCC). Private mutations in the P tumors were present in 32 (68%) and 3 (25%) of the ccRCC and nccRCC cohorts, respectively. Private mutations in the M tumors were present in 32 (68%) of the ccRCC and in 3 (25%) of nccRCC patients (Figure 1a) . Strikingly, SETD2 mutations were private to the M or the P in 70% (16/23), and PTEN alterations were private to the M in 66% (4/6). There were no shared ROS1 mutations, and 83% (5/6) of these were private to the M. In a patient-by-patient analysis, 17% (10) of the pairs shared all SM; 15% (9) shared all of the SM in the M, with only private SM in the P; 25% (15) shared all SM in the P, with private SM only in the M; 42% (25) shared SM in the P-M; and some SM were private to either the P or the M. Only 14 pairs showed two SM in the same gene ( Figure 1b) ; in 57% (8) the M presented a mutation in the same gene as the P but on a different location (convergent evolution), in 28% (4) the M presented both the mutation observed in the P and an additional mutation in the same gene (evolution of metastasis), and in 14% (2) the M showed a subclone of the SM observed in the P (subclonal seeding). CONCLUSIONS: Our data suggest that both linear and parallel progression of metastases is observed in RCC. Although the absence of shared SM in matched pairs may be explained by tumor heterogeneity, metastasis-specific SM may represent cells of the P tumor with advantages to develop metastatic disease giving growth advantages in the studied samples. The extent to which the identified mutations contribute to the development of characteristics of metastatic spread needs to be analyzed further.
INTRODUCTION AND OBJECTIVES: Discovery and understanding of the molecular drivers of clear cell renal cell carcinoma (ccRCC) has led to the development of targeted therapies. Despite advances in these agents, metastatic disease remains largely incurable. Exploration of the biology of metastatic tumors may provide insights into patterns and routes of metastases that could lead to the identification of differences in therapeutic vulnerabilities. We aim to evaluate somatic mutations (SM) associated with organ tropism in a cohort of metastatic ccRCC patients.
METHODS: We identified all patients with ccRCC who had a metastatic tumor sequenced at our institution from 2001 to 2016 using Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT), a next-generation sequencing assay studying a custom panel of 410 (previously 341) targetable genes commonly mutated in cancer. Fishers exact test was used to evaluate associations between recurrent SM and sites of metastasis.
RESULTS: A total of 94 samples from 93 patients were analyzed. Metastatic tissue was obtained from the following sites: 26
